Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong with when investing in for the long term. They are leade ...

Novo Nordisk A/S (NYSE:NVO) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 18, Novo Nordisk A/S ...

Key Points Hims & Hers Health is entering the Canadian market.The company will offer a generic version of semaglutide in the ...

I want you to know I don’t want Novo Nordisk… and the reason that is because if there’s going to be talk about tariffs on ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...

The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to customers. WeightWatchers will work with CenterWell Pharmacy to dispense, manage ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

If you're looking for a top healthcare stock to buy that has much more upside in GLP-1, then going with Eli Lilly or Novo Nordisk can make much more sense at this stage.